Simultaneous cis-platinum and radiotherapy in inoperable or locally advanced squamous cell carcinoma of the head and neck

Giampietro Gasparini, Franco Pozza, Gianfranco Reciter, Gino Antonio Panizzoni, Valentina Cristoferi, Roberto Squaquara, Sandro Dal Fior

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A synergism between cis-platinum (CDDP) and radiotherapy (RT) has been demonstrated both in culture systems and in clinical studies. On the above basis, we planned, in patients with locally advanced or unresectable squamous cell carcinoma of the head and neck, a concomitant treatment with CDDP 80 mg/m2 i.v. every 3 weeks for three doses (days 1.21 and 42) and RT in the primary and in the neck nodes bilaterally, fora total dose of 60-70 Gy. Thirty-five untreated patients with poor prognosis unresectable stage II and stages 111-IV disease were entered in the study and 32 were evaluable. Complete response (CR) rate was 75% (24/32) with 95% confidence limits from 60 to 90% (±15%); 8 cases (25%) achieved a partial response, for an overall response rate of 100%. A significantly higher CR rate and a longer survival rate was observed in patients with good performance status (PS=90-100) and stages II-III. The overall estimated 2-year survival is 46%; 59% for patients who obtained a CR versus 0% for those who achieved only a partial response. Overall the treatment was well tolerated and gastrointestinal and hematologic toxicides were the most common side effects. In conclusion, the combination of CDDP plus RT is a very effective and safe treatment and we recommend such an approach in head and neck squamous cell carcinoma, particularly in those patients with good PS and with unresectable stage II or stage III disease.

Original languageEnglish
Pages (from-to)270-276
Number of pages7
JournalOncology
Volume48
Issue number4
DOIs
Publication statusPublished - 1991

Fingerprint

Cisplatin
Radiotherapy
Neck
Therapeutics
Survival Rate
Carcinoma, squamous cell of head and neck
Survival

Keywords

  • Cis-platinum
  • Combined treatment
  • Head and neck cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gasparini, G., Pozza, F., Reciter, G., Panizzoni, G. A., Cristoferi, V., Squaquara, R., & Dal Fior, S. (1991). Simultaneous cis-platinum and radiotherapy in inoperable or locally advanced squamous cell carcinoma of the head and neck. Oncology, 48(4), 270-276. https://doi.org/10.1159/000226941

Simultaneous cis-platinum and radiotherapy in inoperable or locally advanced squamous cell carcinoma of the head and neck. / Gasparini, Giampietro; Pozza, Franco; Reciter, Gianfranco; Panizzoni, Gino Antonio; Cristoferi, Valentina; Squaquara, Roberto; Dal Fior, Sandro.

In: Oncology, Vol. 48, No. 4, 1991, p. 270-276.

Research output: Contribution to journalArticle

Gasparini, G, Pozza, F, Reciter, G, Panizzoni, GA, Cristoferi, V, Squaquara, R & Dal Fior, S 1991, 'Simultaneous cis-platinum and radiotherapy in inoperable or locally advanced squamous cell carcinoma of the head and neck', Oncology, vol. 48, no. 4, pp. 270-276. https://doi.org/10.1159/000226941
Gasparini, Giampietro ; Pozza, Franco ; Reciter, Gianfranco ; Panizzoni, Gino Antonio ; Cristoferi, Valentina ; Squaquara, Roberto ; Dal Fior, Sandro. / Simultaneous cis-platinum and radiotherapy in inoperable or locally advanced squamous cell carcinoma of the head and neck. In: Oncology. 1991 ; Vol. 48, No. 4. pp. 270-276.
@article{0e1844d88b8941a0b38944352f43f6b1,
title = "Simultaneous cis-platinum and radiotherapy in inoperable or locally advanced squamous cell carcinoma of the head and neck",
abstract = "A synergism between cis-platinum (CDDP) and radiotherapy (RT) has been demonstrated both in culture systems and in clinical studies. On the above basis, we planned, in patients with locally advanced or unresectable squamous cell carcinoma of the head and neck, a concomitant treatment with CDDP 80 mg/m2 i.v. every 3 weeks for three doses (days 1.21 and 42) and RT in the primary and in the neck nodes bilaterally, fora total dose of 60-70 Gy. Thirty-five untreated patients with poor prognosis unresectable stage II and stages 111-IV disease were entered in the study and 32 were evaluable. Complete response (CR) rate was 75{\%} (24/32) with 95{\%} confidence limits from 60 to 90{\%} (±15{\%}); 8 cases (25{\%}) achieved a partial response, for an overall response rate of 100{\%}. A significantly higher CR rate and a longer survival rate was observed in patients with good performance status (PS=90-100) and stages II-III. The overall estimated 2-year survival is 46{\%}; 59{\%} for patients who obtained a CR versus 0{\%} for those who achieved only a partial response. Overall the treatment was well tolerated and gastrointestinal and hematologic toxicides were the most common side effects. In conclusion, the combination of CDDP plus RT is a very effective and safe treatment and we recommend such an approach in head and neck squamous cell carcinoma, particularly in those patients with good PS and with unresectable stage II or stage III disease.",
keywords = "Cis-platinum, Combined treatment, Head and neck cancer",
author = "Giampietro Gasparini and Franco Pozza and Gianfranco Reciter and Panizzoni, {Gino Antonio} and Valentina Cristoferi and Roberto Squaquara and {Dal Fior}, Sandro",
year = "1991",
doi = "10.1159/000226941",
language = "English",
volume = "48",
pages = "270--276",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - Simultaneous cis-platinum and radiotherapy in inoperable or locally advanced squamous cell carcinoma of the head and neck

AU - Gasparini, Giampietro

AU - Pozza, Franco

AU - Reciter, Gianfranco

AU - Panizzoni, Gino Antonio

AU - Cristoferi, Valentina

AU - Squaquara, Roberto

AU - Dal Fior, Sandro

PY - 1991

Y1 - 1991

N2 - A synergism between cis-platinum (CDDP) and radiotherapy (RT) has been demonstrated both in culture systems and in clinical studies. On the above basis, we planned, in patients with locally advanced or unresectable squamous cell carcinoma of the head and neck, a concomitant treatment with CDDP 80 mg/m2 i.v. every 3 weeks for three doses (days 1.21 and 42) and RT in the primary and in the neck nodes bilaterally, fora total dose of 60-70 Gy. Thirty-five untreated patients with poor prognosis unresectable stage II and stages 111-IV disease were entered in the study and 32 were evaluable. Complete response (CR) rate was 75% (24/32) with 95% confidence limits from 60 to 90% (±15%); 8 cases (25%) achieved a partial response, for an overall response rate of 100%. A significantly higher CR rate and a longer survival rate was observed in patients with good performance status (PS=90-100) and stages II-III. The overall estimated 2-year survival is 46%; 59% for patients who obtained a CR versus 0% for those who achieved only a partial response. Overall the treatment was well tolerated and gastrointestinal and hematologic toxicides were the most common side effects. In conclusion, the combination of CDDP plus RT is a very effective and safe treatment and we recommend such an approach in head and neck squamous cell carcinoma, particularly in those patients with good PS and with unresectable stage II or stage III disease.

AB - A synergism between cis-platinum (CDDP) and radiotherapy (RT) has been demonstrated both in culture systems and in clinical studies. On the above basis, we planned, in patients with locally advanced or unresectable squamous cell carcinoma of the head and neck, a concomitant treatment with CDDP 80 mg/m2 i.v. every 3 weeks for three doses (days 1.21 and 42) and RT in the primary and in the neck nodes bilaterally, fora total dose of 60-70 Gy. Thirty-five untreated patients with poor prognosis unresectable stage II and stages 111-IV disease were entered in the study and 32 were evaluable. Complete response (CR) rate was 75% (24/32) with 95% confidence limits from 60 to 90% (±15%); 8 cases (25%) achieved a partial response, for an overall response rate of 100%. A significantly higher CR rate and a longer survival rate was observed in patients with good performance status (PS=90-100) and stages II-III. The overall estimated 2-year survival is 46%; 59% for patients who obtained a CR versus 0% for those who achieved only a partial response. Overall the treatment was well tolerated and gastrointestinal and hematologic toxicides were the most common side effects. In conclusion, the combination of CDDP plus RT is a very effective and safe treatment and we recommend such an approach in head and neck squamous cell carcinoma, particularly in those patients with good PS and with unresectable stage II or stage III disease.

KW - Cis-platinum

KW - Combined treatment

KW - Head and neck cancer

UR - http://www.scopus.com/inward/record.url?scp=0025878879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025878879&partnerID=8YFLogxK

U2 - 10.1159/000226941

DO - 10.1159/000226941

M3 - Article

C2 - 1891167

AN - SCOPUS:0025878879

VL - 48

SP - 270

EP - 276

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -